ProKidney Corp.
Emily Butler has a strong background in statistics and biometrics. Emily'smost recent role was Vice President of Biometrics at ProKidney Corp. starting in December 2022. Prior to that, they worked at GlaxoSmithKline Pharma GmbH as a Principal Statistician from March 2017 to April 2021. Emily also has experience as an Independent Consultant at the University of North Carolina from February 2014 to January 2016. Emily has also worked as a Graduate Teaching Assistant and Statistical Consultant at various universities and organizations throughout their career.
Emily Butler earned their Bachelor's degree in Statistics from Carnegie Mellon University in 2011. Emily then went on to pursue a Doctor of Philosophy (Ph.D.) in Biostatistics at the University of North Carolina at Chapel Hill, completing their studies in 2016. In 2009, they also attended the Summer Institute for Training in Biostatistics at North Carolina State University.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.